Virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein
The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.
1. A method of treating a disease caused by an influenza virus in a subject in need thereof, comprising administering to the subject an interleukin-7 (IL-7) fusion protein, which comprises a human IL-7 protein, an immunoglobulin Fc region, and an oligopeptide, wherein the immunoglobulin Fc region and/or the oligopeptide is linked to the human IL-7 protein, wherein the human IL-7 protein comprises amino acid residues 26-178 of the amino acid sequence set forth in SEQ ID NO: 1, wherein the immunoglobulin Fc region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 9 to 14, and wherein the oligopeptide is selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, and glycine-glycine-glycine.
2. The method of claim 1 , wherein the human IL-7 protein does not comprise amino acid residues 1-25 of the amino acid sequence set forth in SEQ ID NO: 1.
3. The method of claim 1 , wherein the human IL-7 protein consists of amino acid residues 26-178 of the amino acid sequence set forth in SEQ ID NO: 1.
4. The method of claim 1 , wherein the human IL-7 protein consists essentially of amino acid residues 26-178 of the amino acid sequence set forth in SEQ ID NO: 1.
5. The method of claim 1 , wherein the IL-7 fusion protein is represented by the following formula:
N′-Fc-A-IL-7-C′ or (Formula I)
or N′-A-IL-7-Fc-C′ (Formula II)
wherein:
N′ is the N-terminus of the IL-7 fusion protein;
C′ is the C-terminus of the IL-7 fusion protein;
A is the oligopeptide;
Fc is the immunoglobulin Fc region; and
IL-7 is the human IL-7 protein.
6. The method of claim 1 , wherein the IL-7 fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 21, 22, 23, 24, 25, 26, and 27.
7. The method of claim 1 , wherein the influenza virus is H7N9, H5N1, H5N2, H3N2, or H1N1.
8. The method of claim 1 , wherein the IL-7 fusion protein is administered to the subject via a local administration, intramuscular administration, intraperitoneal administration, or subcutaneous administration.
9. The method of claim 8 , wherein the local administration comprises an intranasal administration.
10. A method of enhancing an immune response in a subject infected with an influenza virus, comprising administering to the subject an interleukin-7 (IL-7) fusion protein, which comprises a human IL-7 protein, an immunoglobulin Fc region, and an oligopeptide, wherein the immunoglobulin Fc region and/or the oligopeptide is linked to the human IL-7 protein, wherein the human IL-7 protein comprises amino acid residues 26-178 of the amino acid sequence set forth in SEQ ID NO: 1, and wherein the immunoglobulin Fc region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 9 to 14, and wherein the oligopeptide is selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, and glycine-glycine-glycine.
11. The method of claim 10 , wherein, compared to a corresponding subject that did not receive the administration, (a) the number of immune cells is increased within the lungs of the subject, (b) the amount of airway inflammation is reduced in the subject, or (c) both (a) and (b) after the administration.
12. The method of claim 11 , wherein the immune cells comprise influenza-specific T cells.
13. A method of reducing a risk of an influenza virus infection in a subject in need thereof, comprising administering to the subject an interleukin-7 (IL-7) fusion protein, which comprises a human IL-7 protein, an immunoglobulin Fc region, and an oligopeptide, wherein the immunoglobulin Fc region and/or the oligopeptide is linked to the human IL-7 protein, wherein the human IL-7 protein comprises amino acid residues 26-178 of the amino acid sequence set forth in SEQ ID NO: 1, wherein the immunoglobulin Fc region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 9 to 14, and wherein the oligopeptide is selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, and glycine-glycine-glycine.
14. The method of claim 10 , wherein the IL-7 fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 21, 22, 23, 24, 25, 26, and 27.
15. The method of claim 13 , wherein the IL-7 fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 21, 22, 23, 24, 25, 26, and 27.
16. The method of claim 10 , wherein the IL-7 fusion protein is administered to the subject via a local administration, intramuscular administration, intraperitoneal administration, or subcutaneous administration.
17. The method of claim 13 , wherein the IL-7 fusion protein is administered to the subject via a local administration, intramuscular administration, intraperitoneal administration, or subcutaneous administration.